Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jan 14, 2021 10:50am
137 Views
Post# 32293801

RE:PR - conference

RE:PR - conference

Let's hope he says something more professionally compelling than "mind boggling"!  I hope he listens to how a SeaGen or Immunomedics spoke about their programs and uses their language.  Best in class, entire platform based on target prevalence and activation, industry lead in SORT target, own the space now, reference the academic journals SORT stuff, forefront of investigating the importance of VM and how our MOA disrupts this, etc...


FredTheVoice wrote: THERATECHNOLOGIES TO PRESENT AT THE B. RILEY SECURITIES VIRTUAL ONCOLOGY INVESTOR CONFERENCE Montreal, Canada – January 14, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer and Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer will present at the B. Riley Virtual Oncology Investor Conference on Wednesday, January 20, 2021 at 3:30 p.m. ET. To access the live virtual presentation, please visit the ‘News’ section of the Company’s website. A webcast replay will also be available approximately two hours after the presentation. 

FTV.

 

<< Previous
Bullboard Posts
Next >>